Veloxis Pharmaceuticals A/S

VELO

DK0060048148

Pharmaceuticals

Delayed Nasdaq Copenhagen Other stock markets			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

2022	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
2021	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI

Veloxis Pharmaceuticals A/S Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Earnings Guidance for the Year 2017

May 16, 2017 at 11:22 am

Veloxis Pharmaceuticals A/S reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the first quarter of 2016 the company recognized revenue of USD 4,000,000 compared to USD 1,500,000 in the same period of 2016. Operating loss was USD 5,223,000 compared to USD 6,929,000 in the corresponding period of 2016. Loss before tax was USD 5,617,000 against USD 7,109,000 year ago. Net loss was USD 5,891,000 compared to USD 7,109,000 in the corresponding period of 2016. Basic and diluted LPS were USD 0.00 against USD 0.00 a year ago. Cash used in operating activities were USD 4,173,000 against USD 10,599,000 a year ago. Purchase of property, plant and equipment was USD 113,000.

The company maintains its 2017 outlook of operating loss before the recognition of income from license agreements and before accounting for stock compensation to be in the range of USD 5 15 million.

Latest news about Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	22-06-28	CI
Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	21-04-25	CI
Veloxis Pharmaceuticals A/S Announces Board Appointments	20-02-17	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	20-02-07	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	20-01-30	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	20-01-30	CI
Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	20-01-13	CI
Transcript : Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call	19-11-25
Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	19-11-24	CI
Transcript : Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019	19-11-13
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	19-10-30	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) added to S&P Global BMI Index	19-09-23	CI
Transcript : Veloxis Pharmaceuticals A/S, Q2 2019 Earnings Call, Aug 09, 2019	19-08-09
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-09	CI
Veloxis Pharmaceuticals Revises Outlook for Full Year 2019	19-07-22	CI
Veloxis Pharmaceuticals A/S Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-08	CI
Transcript : Veloxis Pharmaceuticals A/S, Q1 2019 Earnings Call, May 07, 2019	19-05-07
Veloxis Pharmaceuticals Provides Earnings Guidance for the Full Year 2019	19-05-06	CI
Transcript : Veloxis Pharmaceuticals A/S, 2018 Earnings Call, Feb 28, 2019	19-02-28
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-27	CI
Veloxis Pharmaceuticals A/S Announces the Promotion of Mark Hensley to Chief Commercial Officer	19-01-02	CI
FDA Approves New Indication for Envarsus XRA (Tacrolimus Extended-ReleaseTablets)	18-12-19	CI
Transcript : Veloxis Pharmaceuticals A/S, Q3 2018 Earnings Call, Nov 15, 2018	18-11-15
Veloxis Pharmaceuticals A/S Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Maintains Earnings Guidance for the Year 2018	18-11-14	CI

Chart Veloxis Pharmaceuticals A/S

Duration

Period

More charts

Company Profile

Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâs product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâs patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
MERCK KGAA	+7.91%	72.81B
KYOWA KIRIN CO. LTD.	+12.64%	9.13B
SK BIOPHARMACEUTICALS CO., LTD.	-10.56%	5.13B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+58.79%	4.99B
YUHAN CORPORATION	+4.07%	3.9B
BETTA PHARMACEUTICALS CO., LTD.	-16.90%	2.48B
INDIVIOR PLC	+20.84%	2.42B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.13%	2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.31%	2.17B

Specialty & Advanced Pharmaceuticals